Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07489716Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1826 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
SHR-1826
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07489716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489716.